Debora Barton, M.D.
Chief Medical Officer
“I’m excited to be a part of this talented team and share the mission of bringing innovative therapies to treat patients with both hematological malignancies and solid tumors.”
Debora Barton, M.D., is our Chief Medical Officer. Dr. Barton, a clinical oncologist experienced in developing cell therapies, brings to TScan nearly two decades of expertise across global clinical research and development.
Prior to joining TScan, Debora was the Chief Medical Officer at Carisma Therapeutics Inc., where she was responsible for the clinical development of a First-in-Human, First-in-Class cell therapy, including clinical operations, medical affairs, and safety. Previously, Debora was the Senior Vice President, Head of Clinical, Head of Safety at Iovance Biotherapeutics, Inc., where she built a team to run several Phase 2 studies in solid tumors and led clinical efforts related to regulatory interactions. Prior to Iovance, she held positions of increasing responsibility at biotech and pharmaceutical companies including Advanced Accelerator Applications S.A., Celgene Corporation, and Novartis. Debora is a board-certified clinical oncologist (M.D.), and a board member for the American Cancer Society, the Tigerlily Foundation (medical advisory board), and Arovella Therapeutics Ltd (non-executive director). She holds an M.D. from Pontificia Universidade Catolica Sao Paulo and completed her fellowship in Oncology at Federal University of Sao Paulo in Brazil.
When not at TScan, Debora enjoys spending time with her two adopted dogs and advocating for dog rescue and adoption, especially the Pitbull breed. On a warm and sunny day, she might be spotted rock climbing the Shawangunks in New Paltz with her family.